WRAL TV News Show Features Heat Biologics

Courtesy of WRAL.com

Durham’s Heat Biologics is fanning the flames and getting attention.

The clinical-stage company’s promising cancer-fighting technology was featured today on WRAL television, Raleigh’s CBS affiliate, by medical team reporter Allen Mask, M.D.

On Wednesday, June 25, at 3:30 p.m. PST Heat CEO Jeff Wolf will participate in a panel discussion in the North Carolina Pavilion at the BIO International Convention in San Diego.

The panel is titled “Innovative Business/Financing Models to Accelerate Product Development.”

Wolf is one of three panelists who will talk about what worked for their North Carolina biotech companies: being acquired, a licensing deal, and Heat’s successful $25 million IPO last July.

The other panelists are:

  • Steve Butts, president, COO and co-founder of Aerial BioPharma. In January 2013 Aerial sold rights to its clinical-stage narcolepsy drug, ADX-N05, for a potential $397 million to Jazz Pharmaceuticals of Dublin, Ireland.
  • Mike Grey, president and CEO of Lumena Pharmaceuticals and a venture partner with Pappas Ventures. In May 2014, Shire bought former Research Triangle Park-based Lumena for some $260 million. Lumena was founded by Pappas Ventures.

The panel will be moderated by Peter Ginsberg, vice president for Business and Technology Development at NCBiotech, which has invested in 20 emerging biopharma companies through NCBiotech’s loan program during the past fiscal year. Both Heat and Aerial have received loans from NCBiotech.

The North Carolina pavilion, Booth #1727, features a full presentation schedule, featuring talks by many of its sponsors.

BIO
Grifols tour
Grifols celebrates 50 years in Clayton

Grifols, a global manufacturer of plasma-based medicines headquartered in Barcelona, Spain, held a celebration to mark 50 years in Clayton, NC.

Grifols acquired the Johnston County facility in 2011 from Talecris Biotherapeutics, turning Grifols into a top-three plasma-sector powerhouse. 

Read more »
FDB aerial
FUJIFILM Diosynth Biotechnologies to double Holly Springs biomanufacturing campus

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO), plans to invest $1.2 billion to double the size of its manufacturing facility currently under construction in Holly Springs.

When completed, the site will be the largest end-to-end cell culture CDMO facility in North America, housing state-of-the-art biopharmaceutical manufacturing equipment and technology, including two large manufacturing suites for large-scale monoclonal antibody drug substance and drug product manufacturing. 

Read more »
Cell CEO Pace
Single-cell solution: How Cell Microsystems wants to help scientists speed therapeutic breakthroughs

Gary Pace, PhD, remembers precisely when he realized that Cell Microsystems had to change. It was 2014, and Pace had recently signed on as CEO of the UNC-Chapel Hill spinout company. He sat in a meeting listening to feedback from potential customers. “We had convened a group of academic scientists talking about what they need. Have they tried our product? Where can we take it?” he recalled. “It was at that meeting that I realized that we couldn’t take a technology perspective on the product.

Read more »
scroll back to top of page